Coherus BioSciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Coherus BioSciences, Inc.
Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form
Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.
Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal
Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.
Coherus Files On-Body Pegfilgrastim, Says ‘People Talk’ On Potential Rivals
Having previously underlined that it would not tell the market the exact moment it filed its proposed biosimilar pegfilgrastim on-body injector device, Coherus BioSciences has now confirmed a filing was completed late last year.
Coherus Makes U-Turn On Eylea Biosimilar With Klinge BioPharma Deal
Buoyed by the recent launch and leverage of its biosimilar ranibizumab biosimilar, Coherus BioSciences has brokered a deal with Klinge BioPharma/Formycon for the commercialization rights to the firms’ Eylea (aflibercept) biosimilar candidate
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.